1、 1.Constant currencies(cc),core results and free cash flow are non-IFRS measures.An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report.Unless otherwise noted,all growth rates in this Release refer to same period in prior year.2.Please see detailed guidance ass

2、umptions on page 7.3.As defined on page 35 of the Condensed Financial Report,Continuing operations include the retained business activities of Novartis,comprising the innovative medicines business and the continuing corporate activities,and Discontinued operations include operational results from th

3、e Sandoz business.Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland https:/ https:/ Ad hoc announcement pursuant to Art.53 LR FINANCIAL RESULTS|FINANZERGEBNISSE Novartis continues strong momentum of sales growth with margin expansion,reaches key innovation milestones

4、 in 2024 Full year Net sales grew+12%(cc1,+11%USD)with core operating income1 up+22%(cc,+19%USD)o Sales growth driven by continued strong performance from Entresto(+31%cc),Cosentyx(+25%cc),Kesimpta(+49%cc),Kisqali(+49%cc),Pluvicto(+42%cc)and Leqvio(+114%cc)o Core operating income margin1 38.7%,+330

5、basis points(cc),mainly driven by higher net sales Operating income grew+55%(cc,+49%USD);net income up+45%(cc,+39%USD)Core EPS1 grew+24%(cc,+21%USD)to USD 7.81 Free cash flow1 of USD 16.3 billion(+24%USD)driven by higher net cash flows from operating activities Fourth quarter Net sales grew+16%(cc,+

6、15%USD)with core operating income up+29%(cc,+27%USD)o Sales growth driven by continued strong performance from Entresto(+34%cc),Kesimpta(+49%cc),Kisqali(+52%cc),Cosentyx(+24%cc),and Leqvio(+83%cc)Selected innovation milestones:o Scemblix FDA accelerated approval for 1L Ph+CML-CP o Kisqali EC approva